MedTrace Logo

Phase I Biomarker Study (BMS-936558)

NCT01358721 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2021-10-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.

Conditions

Interventions

DRUG

BMS-936558 (Anti-PD-1)

Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response

DRUG

BMS-936558 (Anti-PD-1)

Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response

DRUG

BMS-936558 (Anti-PD-1)

Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-23
Primary Completion
2014-12-01
Completion
2019-05-22

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01358721 on ClinicalTrials.gov